ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Gilead Sciences will license to seven Indian generic pharmaceutical firms the rights to sell its blockbuster hepatitis C drug Sovaldi in developing countries such as India and South Africa. Sovaldi (sofosbuvir) sells in the U.S. for about $1,000 per pill or $85,000 for a full course of treatment. The Indian companies will likely sell the medication at a far lower price. They will pay a 7% royalty to Gilead, which in turn will help them develop their manufacturing processes. The nonprofit Doctors Without Borders is criticizing the pact for not including middle-income countries such as China, Brazil, and Thailand.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X